Non-amyloid monoclonal immunoglobulin deposition disease

Summary

Non-amyloid monoclonal immunoglobulin deposition disease (MONDO:0019463) is a disease. A subtype of plasma cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-amyloid monoclonal immunoglobulin deposition disease
Mondo ID	MONDO:0019463
Orphanet	86861
UMLS	C5394673
MedGen	1716147
GARD	0019073
Is cancer (heuristic)	no

Also known as: non-amyloid MIDD · Randall disease

Disease family

This is a subtype of plasma cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm › non-amyloid monoclonal immunoglobulin deposition disease

Related subtypes (6): refractory plasma cell neoplasm, plasmacytoma, leukemoid reaction, plasma cell myeloma, plasma cell leukemia, heavy chain disease

Subtypes (3): heavy chain deposition disease, light and heavy chain deposition disease, light chain deposition disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.